Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.

CMS proposes new DRG with higher average payment rate for CAR-T therapy but signals new technology add-on payments will no longer be awarded to supplement reimbursement. 

But should a patient with little connection to a 340B covered entity other than through a telehealth visit be considered eligible for a discounted drug under the program?

Manufacturers seek additional flexibility from Medicare to facilitate home infusions as surveys indicate patient visits to physician offices have dropped by 40% to 68% in recent weeks, signaling a decline in adherence for physician-administered drugs. 

Medicare Part B spending on discarded, weight-based drugs sold in single-use vials is around $725m annually. The National Academies of Science, Engineering and Medicine is evaluating strategies to reduce the waste.

Study's finding is somewhat surprising for Europe, given the greater national involvement in drug prices in the region; ASCO and ESMO value frameworks don't appear to drive oncology pricing decisions regardless of the reimbursement system.